Technology Brief: Biomarkers predicting response to immunosuppression in myelodysplastic syndromes

Docket Number: 07A056

Summary	• MDS (myelodysplastic syndromes) may be treated by immuno-suppressive therapies such as anti-thymocyte globulin. • Patient responses to these therapies is variable. Hence methods are needed to better predict responses to immuno-suppressive therapy. • A Moffitt researcher has discovered biomarkers for predicting response of MDS patients to therapy with anti-thymocyte globulin.
Features and Benefits	• The method is based on T-cell surface markers that can be assayed by routine flow cytometry methods. • The markers are well known and can be measured with standard reagents. • Simple ratios of certain T-cell populations predict which patients will respond to therapy with anti-thymocyte globulin.
Stage of Development	Retrospective proof of concept. Clinical trials are under way.
Inventor	Dr. P. K. Eppling-Burnette
Publication and Patent	J.X. Zou et al. (2009) Leukemia 23:1288-1296. US Patent Pending

Contact Information:

Haskell Adler PhD MBA
Senior Licensing Manager
Email: haskell.adler@moffitt.org
Telephone: 813-745-6596

H. Lee Moffitt Cancer Center and Research Institute, Inc.
Office of Technology Management and Commercialization
12902 Magnolia Drive MRC-TTO
Tampa, FL 33612
Website: http://www.moffitt.org/OTMC